Hege S Haugnes1,2, Niels Christian Stenklev2,3, Marianne Brydøy4, Olav Dahl4,5, Tom Wilsgaard6, Einar Laukli3, Sophie D Fosså7,8. 1. a Department of Oncology , University Hospital of North Norway , Tromsø , Norway. 2. b Institute of Clinical Medicine , UIT- The Arctic University , Tromsø , Norway. 3. c Department of Ear, Nose and Throat , University Hospital of North Norway , Tromsø , Norway. 4. d Department of Oncology , Haukeland University Hospital , Bergen , Norway. 5. e Section of Oncology, Institute of Clinical Medicine , University of Bergen , Bergen , Norway. 6. f Institute of Community Medicine , UIT- The Arctic University , Tromsø , Norway. 7. g Division of Cancer Medicine and Radiotherapy , Oslo University Hospital , Oslo , Norway. 8. h Institute of Clinical Medicine , University of Oslo , Oslo , Norway.
Abstract
BACKGROUND: Hearing loss is a well-known long-term effect after cisplatin-based chemotherapy (CBCT) in testicular cancer survivors (TCS), but longitudinal data are sparse. We evaluate hearing loss and the impact of age in TCS treated with CBCT in this longitudinal study. MATERIAL AND METHODS: Forty-six TCS treated with CBCT 1980-1994 with audiograms (0.25-8 kHz) pre-chemotherapy (PRE) and at a follow-up survey (SURV) after median 10 years were included (cases). Audiograms at SURV from 46 age-matched TCS without CBCT were included as controls. Linear regression was performed to evaluate predictors for change in the hearing threshold level (HTL) from PRE to SURV. Two definitions of a audiogram-defined hearing loss was applied if: (1) mean HTL for both ears exceeded 20 dB at any frequency 0.25-8 kHz (American Speech-Language-Hearing Association (ASHA) definition) and (2) average HTL for the frequencies 0.5, 1, 2 and 4 kHz exceeded 20 dB (WHO-M4 definition). Self-reported hearing impairment (SURV) was assessed by a questionnaire. RESULTS: Age and cisplatin dose was significantly associated with a greater change in HTL for the frequencies 2-8 kHz. For the 8 kHz frequency, each 100 mg increase in cumulative cisplatin dose was associated with a deterioration of 3.6 dB (95% CI 1.8-5.3, p < .001). The prevalence of hearing loss (ASHA) among cases was 33% PRE, 70% at SURV and 65% among controls at SURV (cases vs. controls, p = .66). According to M4, the prevalence of hearing loss among cases was 6.5% PRE, 13% at SURV and 2.2% among controls at SURV (cases vs. controls, p = .049). Twenty-nine percent of cases, and 33% of controls (p = .70) reported hearing impairment at SURV. CONCLUSION: Cisplatin is associated with a hearing loss particularly at higher frequencies. Age appear to be an important factor for hearing loss regardless of treatment. The ASHA definition overestimates the hearing problem.
BACKGROUND:Hearing loss is a well-known long-term effect after cisplatin-based chemotherapy (CBCT) in testicular cancer survivors (TCS), but longitudinal data are sparse. We evaluate hearing loss and the impact of age in TCS treated with CBCT in this longitudinal study. MATERIAL AND METHODS: Forty-six TCS treated with CBCT 1980-1994 with audiograms (0.25-8 kHz) pre-chemotherapy (PRE) and at a follow-up survey (SURV) after median 10 years were included (cases). Audiograms at SURV from 46 age-matched TCS without CBCT were included as controls. Linear regression was performed to evaluate predictors for change in the hearing threshold level (HTL) from PRE to SURV. Two definitions of a audiogram-defined hearing loss was applied if: (1) mean HTL for both ears exceeded 20 dB at any frequency 0.25-8 kHz (American Speech-Language-Hearing Association (ASHA) definition) and (2) average HTL for the frequencies 0.5, 1, 2 and 4 kHz exceeded 20 dB (WHO-M4 definition). Self-reported hearing impairment (SURV) was assessed by a questionnaire. RESULTS: Age and cisplatin dose was significantly associated with a greater change in HTL for the frequencies 2-8 kHz. For the 8 kHz frequency, each 100 mg increase in cumulative cisplatin dose was associated with a deterioration of 3.6 dB (95% CI 1.8-5.3, p < .001). The prevalence of hearing loss (ASHA) among cases was 33% PRE, 70% at SURV and 65% among controls at SURV (cases vs. controls, p = .66). According to M4, the prevalence of hearing loss among cases was 6.5% PRE, 13% at SURV and 2.2% among controls at SURV (cases vs. controls, p = .049). Twenty-nine percent of cases, and 33% of controls (p = .70) reported hearing impairment at SURV. CONCLUSION:Cisplatin is associated with a hearing loss particularly at higher frequencies. Age appear to be an important factor for hearing loss regardless of treatment. The ASHA definition overestimates the hearing problem.
Authors: Shirin Ardeshirrouhanifard; Sophie D Fossa; Robert Huddart; Patrick O Monahan; Chunkit Fung; Yiqing Song; M Eileen Dolan; Darren R Feldman; Robert J Hamilton; David Vaughn; Neil E Martin; Christian Kollmannsberger; Paul Dinh; Lawrence Einhorn; Robert D Frisina; Lois B Travis Journal: Ear Hear Date: 2022 May/Jun Impact factor: 3.562
Authors: Matthew A Ingersoll; Emma A Malloy; Lauryn E Caster; Eva M Holland; Zhenhang Xu; Marisa Zallocchi; Duane Currier; Huizhan Liu; David Z Z He; Jaeki Min; Taosheng Chen; Jian Zuo; Tal Teitz Journal: Sci Adv Date: 2020-12-02 Impact factor: 14.136
Authors: Mette Pernille Myklebust; Anna Thor; Benedikte Rosenlund; Peder Gjengstø; Ása Karlsdottir; Marianne Brydøy; Bogdan S Bercea; Christian Olsen; Ida Johnson; Mathilde I Berg; Carl W Langberg; Kristine E Andreassen; Anders Kjellman; Hege S Haugnes; Olav Dahl Journal: Sci Rep Date: 2021-08-02 Impact factor: 4.379